Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03684980 · ClinicalTrials.gov registry record · Early Phase 1

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

A Early Phase 1 study of Central Nervous System Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Early Phase 1
Development phase
58
Enrollment target
11
Study locations

NCT03684980 is a Early Phase 1 study of Central Nervous System Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 58 participants, below the 101-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (43% lower). The trial reports 11 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03684980, a Early Phase 1 study of Central Nervous System Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
58 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.

Conditions Studied

Central Nervous System Lymphoma

Interventions

  • DRUG Rituximab
  • DRUG Methotrexate
  • DRUG leucovorin
  • DRUG Glucarpidase

Study Locations (11)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati
  • Cleveland Clinic (Data Collection and Specimen Collection) - Cleveland

Alabama

  • University of Alabama at Birmingham - Birmingham

Massachusetts

  • Dana Farber Cancer Institute (Data Collection and Specimen Analysis) - Boston

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2018-11-14
Est. Completion 2027-11
Phase Early Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03684980

The ClinicalTrials.gov registry entry for NCT03684980 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (43% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Central Nervous System Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Rituximab is the first listed.

NCT03684980 reports 11 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, Ohio.

Frequently Asked Questions

What is clinical trial NCT03684980 about?

NCT03684980 is a clinical study titled "LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma". The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.

What is the current status of trial NCT03684980?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 58 participants. The study started on 2018-11-14. Estimated completion is 2027-11.

What conditions does trial NCT03684980 study?

This clinical trial studies the following conditions: Central Nervous System Lymphoma.

What interventions are being tested in trial NCT03684980?

The interventions under investigation include: Rituximab (DRUG), Methotrexate (DRUG), leucovorin (DRUG), Glucarpidase (DRUG).

Who is sponsoring clinical trial NCT03684980?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03684980 being conducted?

This trial has 11 study locations across Alabama, Massachusetts, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Central Nervous System Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Central Nervous System Lymphoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.